AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06272227
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
Trial: NCT05987423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection
Trial: NCT05115955
Drug: DS group
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
Trial: NCT05115955
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
Trial: NCT05143905
Drug: AZD7503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
Trial: NCT05143905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive placebo by SC injection
Trial: NCT04695613
Drug: Aminoacid
RxNorm normalized name: Acid-aminoacid ligase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amino acid infusion 150 ml/kg/hr starting preoperative
Trial: NCT05622162
Drug: Radiopharmaceutical 18F-Fluorocholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study.
Trial: NCT04976270
Drug: GLPG3667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3667 capsules
Trial: NCT06277466
Drug: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Trial: NCT04976270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT06280794
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
Trial: NCT05580588
Drug: SPH4336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg SPH4336 PO QD
Trial: NCT05744219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04514302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
Trial: NCT05974267
Drug: M5717 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
Trial: NCT05227690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Trial: NCT04646564
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Trial: NCT06593366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
Trial: NCT06623526
Drug: YHR2402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug: YHR2402
Trial: NCT06623526
Drug: YHR2402+YHR2403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug: YHR2402+YHR2403
Trial: NCT06434597
Drug: SPH5030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH5030：Oral, QD, 600mg
Trial: NCT05362955
Drug: Intravaginal 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
Trial: NCT05462613
Drug: FOLFIRI or FOLFOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 2 weeks according to investigator practice
Trial: NCT03941132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.
Trial: NCT06582888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT05303727
Drug: Cyclophosphamide injection
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day for 2 days in cord blood stem cell transplantation
Trial: NCT05303727
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
Trial: NCT05509153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
Trial: NCT06477406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An active placebo containing supplemental terpenes matched to the high-CBD product.
Trial: NCT04941443
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
Trial: NCT05247528
Drug: MANP
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel designer peptide to represent a pGC-A/cGMP therapeutic
Trial: NCT05247528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT06449937
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.
Trial: NCT05402371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo soft gel capsule
Trial: NCT05973149
Drug: QLH12016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to the scheme description
Trial: NCT06703268
Drug: HSK7653 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 10 mg Q2W
Trial: NCT06703268
Drug: Daily DPP-4 inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily DPP-4 inhibitor
Trial: NCT04951167
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the form of infusion
Trial: NCT04951167
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the form of bolus
Trial: NCT04772742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - solution for infusion
Trial: NCT06637865
Drug: IMP761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT06637865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT06096259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
Trial: NCT06795503
Drug: Docetaxel plus cyclophosphamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.
Trial: NCT06079801
Drug: anti-CGRP-mAbs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
Trial: NCT05536440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV or SC
Trial: NCT06566508
Drug: Calcium Hydroxide Intracanal medication
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Hydroxide Intracanal medication
Trial: NCT03180450
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
Trial: NCT03806478
Drug: APH-1105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
Trial: NCT06564272
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
Trial: NCT05093907
Drug: BEY1107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer once daily, PO, 3-week continuous dose.
Trial: NCT05778227
Drug: Ethylene Diamine Tetra Acetic acid
RxNorm normalized name: Ethylene-diamine
DrugBank: Ethylenediamine (DB14189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
Trial: NCT05778227
Drug: smearOFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
Trial: NCT05778227
Drug: Maleic acid
RxNorm normalized name: Maleic Acid
DrugBank: Maleic acid (DB04299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
Trial: NCT04918147
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Trial: NCT05624710
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB054707 75 mg will be administered orally on Day 1.
Trial: NCT06641089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06105671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered placebo
Trial: NCT05739942
Drug: [177Lu]Lu-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical solution for infusion
Trial: NCT05739942
Drug: [68Ga]Ga-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
Trial: NCT05249959
Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Trial: NCT06157502
Drug: Shuxuening Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
Trial: NCT05288374
Drug: Celecoxib 100 mg
RxNorm normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Trial: NCT05288374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Trial: NCT05563246
Drug: LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05563246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06649630
Drug: NNC0442-0344 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.
Trial: NCT06649630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.
Trial: NCT04987944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching active drug
Trial: NCT06001177
Drug: KAN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose KAN-101 Intravenous (IV) Infusion
Trial: NCT06001177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Intravenous (IV) Infusion
Trial: NCT04725357
Drug: Meloxicam 15 mg
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
Trial: NCT05558007
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of a placebo pill
Trial: NCT05558007
Drug: Topical Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.5 mL of placebo
Trial: NCT05975047
Drug: LIV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
Trial: NCT05975047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo across Part A and B of the study
Trial: NCT05991583
Drug: IBB0979
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBB0979 should be subcutaneous injected，qw
Trial: NCT06506305
Drug: FB1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal (IVT) injection
Trial: NCT05542407
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
Trial: NCT05451407
Drug: TQB2618 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized IgG4 mab targeting TIM-3
Trial: NCT06309394
Drug: INCB099280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
Trial: NCT06417476
Drug: Calcium Formate
RxNorm normalized name: Calcium formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Trial: NCT06417476
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
Trial: NCT06417476
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
Trial: NCT05190562
Drug: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet
RxNorm normalized name: zinc sulfate 110 MG (zinc 25 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
Trial: NCT05207176
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
Trial: NCT04923607
Drug: TQC2731
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC2731 injection
Trial: NCT04923607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo with no active ingredients
Trial: NCT05631678
Drug: Rifampicin; ASK120067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
Trial: NCT05948553
Drug: Intervention A Fluoxetine Hydrochloride (HCl)
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Trial: NCT05948553
Drug: Intervention A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Trial: NCT04221750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
Trial: NCT06701344
Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days
Trial: NCT05238961
Drug: [18F]DPA-714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational PET Tracer \[18F\]DPA-714
Trial: NCT06005324
Drug: TFHX Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Trial: NCT05196711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo
Trial: NCT06702566
Drug: PD-1 and PD-L1 inhibitor
RxNorm normalized name: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.